4//SEC Filing
DAVIS STEPHEN 4
Accession 0001209191-24-001269
CIK 0001070494other
Filed
Jan 8, 7:00 PM ET
Accepted
Jan 9, 6:00 PM ET
Size
10.0 KB
Accession
0001209191-24-001269
Insider Transaction Report
Form 4
DAVIS STEPHEN
EVP, CFO AND CBO
Transactions
- Sale
Common Stock
2024-01-08$29.96/sh−3,732$111,811→ 96,521 total - Exercise/Conversion
Restricted Stock Units
2024-01-06−9,528→ 0 total→ Common Stock (9,528 underlying) - Exercise/Conversion
Common Stock
2024-01-06+9,528→ 100,253 total
Footnotes (5)
- [F1]Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.
- [F2]Includes 1,594 shares acquired by the Reporting Person under the Issuer's 2004 Employee Stock Purchase Plan on May 15, 2023. On October 6, 2023, the Reporting Person filed a Form 4 which reported the same acquisition of shares in a footnote to Table I, Column 5, but inadvertently omitted such shares from the total in Table I, Column 5. The May 15, 2023 acquisition by the Reporting Person under the Issuer's 2004 Employee Stock Purchase Plan is now correctly included in Table I, Column 5 of this Form 4.
- [F3]The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.63 to $29.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- [F5]The restricted stock units vest in four equal annual installments beginning January 6, 2021.
Documents
Issuer
ACADIA PHARMACEUTICALS INC
CIK 0001070494
Entity typeother
Related Parties
1- filerCIK 0001131146
Filing Metadata
- Form type
- 4
- Filed
- Jan 8, 7:00 PM ET
- Accepted
- Jan 9, 6:00 PM ET
- Size
- 10.0 KB